Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Epstein-Barr Virus | Research

Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya

Authors: Perez K. Olewe, Shehu Shagari Awandu, Elly O. Munde, Samuel B. Anyona, Evans Raballah, Asito S. Amolo, Sidney Ogola, Erick Ndenga, Clinton O. Onyango, Rosemary Rochford, Douglas J. Perkins, Collins Ouma

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Epstein Barr virus (EBV)-associated endemic Burkitt’s Lymphoma pediatric cancer is associated with morbidity and mortality among children resident in holoendemic Plasmodium falciparum regions in western Kenya. P. falciparum exerts strong selection pressure on sickle cell trait (SCT), alpha thalassemia (-α3.7/αα), glucose-6-phosphate dehydrogenase (G6PD), and merozoite surface protein 2 (MSP-2) variants (FC27, 3D7) that confer reduced malarial disease severity. The current study tested the hypothesis that SCT, (-α3.7/αα), G6PD mutation and (MSP-2) variants (FC27, 3D7) are associated with an early age of EBV acquisition.

Methods

Data on infant EBV infection status (< 6 and ≥ 6–12 months of age) was abstracted from a previous longitudinal study. Archived infant DNA (n = 81) and mothers DNA (n = 70) samples were used for genotyping hemoglobinopathies and MSP-2. The presence of MSP-2 genotypes in maternal DNA samples was used to indicate infant in-utero malarial exposure. Genetic variants were determined by TaqMan assays or standard PCR. Group differences were determined by Chi-square or Fisher’s analysis. Bivariate regression modeling was used to determine the relationship between the carriage of genetic variants and EBV acquisition.

Results

EBV acquisition for infants < 6 months was not associated with -α3.7/αα (OR = 1.824, P = 0.354), SCT (OR = 0.897, P = 0.881), or G6PD [Viangchan (871G > A)/Chinese (1024 C > T) (OR = 2.614, P = 0.212)] and [Union (1360 C > T)/Kaiping (1388G > A) (OR = 0.321, P = 0.295)]. There was no relationship between EBV acquisition and in-utero exposure to either FC27 (OR = 0.922, P = 0.914) or 3D7 (OR = 0.933, P = 0.921). In addition, EBV acquisition in infants ≥ 6–12 months also showed no association with -α3.7/αα (OR = 0.681, P = 0.442), SCT (OR = 0.513, P = 0.305), G6PD [(Viangchan (871G > A)/Chinese (1024 C > T) (OR = 0.640, P = 0.677)], [Mahidol (487G > A)/Coimbra (592 C > T) (OR = 0.948, P = 0.940)], [(Union (1360 C > T)/Kaiping (1388G > A) (OR = 1.221, P = 0.768)], African A (OR = 0.278, P = 0.257)], or in utero exposure to either FC27 (OR = 0.780, P = 0.662) or 3D7 (OR = 0.549, P = 0.241).

Conclusion

Although hemoglobinopathies (-α3.7/αα, SCT, and G6PD mutations) and in-utero exposure to MSP-2 were not associated with EBV acquisition in infants 0–12 months, novel G6PD variants were discovered in the population from western Kenya. To establish that the known and novel hemoglobinopathies, and in utero MSP-2 exposure do not confer susceptibility to EBV, future studies with larger sample sizes from multiple sites adopting genome-wide analysis are required.
Appendix
Available only for authorised users
Literature
1.
Queiroga EM, Gualco G, Weiss LM, Dittmer DP, Araujo I, Klumb CEN, et al. Burkitt Lymphoma in Brazil is characterized by geographically distinct clinicopathologic features. Am J Clin Pathol. 2008;130(6):946–56.PubMedCrossRef
2.
Orem J, Mbidde EK, Lambert B, Sanjose Sd, Weiderpass E. Burkitt’s lymphoma in Africa, a review of the epidemiology and etiology. Afr Health Sci. 2007;7(3):166.PubMedPubMedCentral
3.
4.
Suh JK, Gao YJ, Tang JY, Jou ST, Lin DT, Takahashi Y, et al. Clinical characteristics and treatment outcomes of Pediatric patients with Non-Hodgkin Lymphoma in East Asia. Cancer Res Treat. 2020;52(2):359–68.PubMedCrossRef
5.
Walter MO, R R, M MA, L WM. A M, C W,. Burkitt’s lymphoma in Kenya: geographical, age, gender and ethnic distribution. 2004.
6.
Rainey JJ, Mwanda WO, Wairiumu P, Moormann AM, Wilson ML, Rochford R. Spatial distribution of Burkitt’s lymphoma in Kenya and association with malaria risk. Trop Med Int Health. 2007;12(8):936–43.PubMedCrossRef
7.
8.
Derby KS, Sullivan KM, Ruth LJ, Williams TN, Suchdev PS. The relationship between inherited blood disorders and iron biomarkers among young children in Kenya. FASEB J. 2013;27(1supplement):1078–8.
9.
Byrd KA, Williams TN, Lin A, Pickering AJ, Arnold BF, Arnold CD, et al. Sickle cell and α+-Thalassemia Traits Influence the Association between Ferritin and Hepcidin in rural kenyan children aged 14–26 months. J Nutr. 2018;148(12):1903–10.PubMedPubMedCentralCrossRef
10.
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Williams TN, et al. Global distribution of the sickle cell gene and geographical confirmation of the malaria hypothesis. Nat Commun. 2010;1:104.PubMedCrossRef
11.
Piel FB, Patil AP, Howes RE, Nyangiri OA, Gething PW, Dewi M, et al. Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet. 2013;381(9861):142–51.PubMedPubMedCentralCrossRef
12.
Croke K, Ishengoma DS, Francis F, Makani J, Kamugisha ML, Lusingu J, et al. Relationships between sickle cell trait, malaria, and educational outcomes in Tanzania. BMC Infect Dis. 2017;17(1):568.PubMedPubMedCentralCrossRef
13.
Gong L, Parikh S, Rosenthal PJ, Greenhouse B. Biochemical and immunological mechanisms by which sickle cell trait protects against malaria. Malar J. 2013;12(1):317.PubMedPubMedCentralCrossRef
14.
Mulama DH, Bailey JA, Foley J, Chelimo K, Ouma C, Jura WGZO, et al. Sickle cell trait is not associated with endemic Burkitt lymphoma: an ethnicity and malaria endemicity-matched case–control study suggests factors controlling EBV may serve as a predictive biomarker for this pediatric cancer. Int J Cancer. 2014;134(3):645–53.PubMedCrossRef
15.
Howes RE, Piel FB, Patil AP, Nyangiri OA, Gething PW, Dewi M et al. G6PD Deficiency Prevalence and estimates of affected populations in Malaria endemic countries: a geostatistical model-based map. PLoS Med. 2012;9(11).
16.
Cappellini MD, Fiorelli G. Glucose-6-phosphate dehydrogenase deficiency. Lancet. 2008;371(9606):64–74.PubMedCrossRef
17.
Donati D, Espmark E, Kironde F, Mbidde EK, Kamya M, Lundkvist A, et al. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis. 2006;193(7):971–7.PubMedCrossRef
18.
19.
Osier FHA, Murungi LM, Fegan G, Tuju J, Tetteh KK, Bull PC, et al. Allele-specific antibodies to Plasmodium falciparum merozoite surface protein-2 and protection against clinical malaria. Parasite Immunol. 2010;32(3):193–201.PubMedPubMedCentralCrossRef
20.
21.
Daud II, Ogolla S, Amolo AS, Namuyenga E, Simbiri K, Bukusi EA, et al. Plasmodium falciparum infection is associated with Epstein-Barr virus reactivation in pregnant women living in malaria holoendemic area of western Kenya. Matern Child Health J. 2015;19(3):606–14.PubMedPubMedCentralCrossRef
22.
Piriou E, Asito AS, Sumba PO, Fiore N, Middeldorp JM, Moormann AM, et al. Early Age at Time of Primary Epstein–Barr virus infection results in poorly controlled viral infection in Infants from Western Kenya: clues to the etiology of endemic Burkitt Lymphoma. J Infect Dis. 2012;205(6):906–13.PubMedPubMedCentralCrossRef
23.
Moormann AM, Chelimo K, Sumba OP, Lutzke ML, Ploutz-Snyder R, Newton D, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis. 2005;191(8):1233–8.PubMedCrossRef
24.
Rochford R. Epstein-Barr virus infection of infants: implications of early age of infection on viral control and risk for Burkitt lymphoma. Boletín Médico del Hospital Infantil de México. 2016;73(1):41–6.PubMedCrossRef
25.
Rainey JJ, Omenah D, Sumba PO, Moormann AM, Rochford R, Wilson ML. Spatial clustering of endemic Burkitt’s lymphoma in high-risk regions of Kenya. Int J Cancer. 2007;120(1):121–7.PubMedCrossRef
26.
Ndenga B, Githeko A, Omukunda E, Munyekenye G, Atieli H, Wamai P, et al. Population dynamics of malaria vectors in western Kenya highlands. J Med Entomol. 2006;43(2):200–6.PubMedCrossRef
27.
Kapesa A, Kweka EJ, Atieli H, Afrane YA, Kamugisha E, Lee MC, et al. The current malaria morbidity and mortality in different transmission settings in western Kenya. PLoS ONE. 2018;13(8):e0202031.PubMedPubMedCentralCrossRef
28.
Wanjiku CM, Njuguna F, Chite Asirwa F, Mbunya S, Githinji C, Roberson C, et al. Establishing care for sickle cell disease in western Kenya: achievements and challenges. Blood Adv. 2019;3(Suppl 1):8–10.PubMedPubMedCentralCrossRef
29.
Ogolla SO, Daud II, Asito AS, Sumba OP, Ouma C, Vulule J, et al. Reduced Transplacental transfer of a subset of Epstein-Barr Virus-Specific antibodies to neonates of mothers infected with Plasmodium falciparum Malaria during pregnancy. Clin Vaccine Immunol. 2015;22:1197–205.PubMedPubMedCentralCrossRef
30.
Kosiyo P, Otieno W, Gitaka J, Munde EO, Ouma C. Association between haematological parameters and sickle cell genotypes in children with Plasmodium falciparum malaria resident in Kisumu County in Western Kenya. BMC Infect Dis. 2020;20(1):887.PubMedPubMedCentralCrossRef
31.
Liu O, Miles, Fisher, Weatherall C. Rapid detection of α-thalassaemia deletions and α-globin gene triplication by multiplex polymerase chain reactions. Br J Haematol. 2000;108(2):295–9.PubMedCrossRef
32.
Zhang L, Yang Y, Liu R, Li Q, Yang F, Ma L, et al. A multiplex method for detection of glucose-6-phosphate dehydrogenase (G6PD) gene mutations. Int J Lab Hematol. 2015;37(6):739–45.PubMedPubMedCentralCrossRef
33.
de-The G. Is Burkitt’s lymphoma related to perinatal infection by Epstein-Barr. virus? Lancet. 1977;1(8007):335–8.PubMedCrossRef
34.
Allen SJ, O’Donnell A, Alexander ND, Alpers MP, Peto TE, Clegg JB, et al. alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci USA. 1997;94(26):14736–41.PubMedPubMedCentralCrossRef
35.
Mbanefo EC, Ahmed AM, Titouna A, Elmaraezy A, Trang NTH, Phuoc Long N et al. Association of glucose-6-phosphate dehydrogenase deficiency and malaria: a systematic review and meta-analysis. Sci Rep. 2017;7.
36.
Aidoo M, Terlouw DJ, Kolczak MS, McElroy PD, ter Kuile FO, Kariuki S, et al. Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet. 2002;359(9314):1311–2.PubMedCrossRef
37.
Williams TN, Weatherall DJ. World distribution, Population Genetics, and Health Burden of the Hemoglobinopathies. Cold Spring Harb Perspect Med. 2012;2(9).
38.
Buckle G, Maranda L, Skiles J, Ong’echa JM, Foley J, Epstein M, et al. Factors influencing survival among kenyan children diagnosed with endemic Burkitt lymphom between 2003 and 2011: a historical cohort study. Int J Cancer. 2016;139(6):1231–40.PubMedPubMedCentralCrossRef
39.
Shah T, Hussain W, Ali N, Sardar S, Ishaq M, Ur Rahman M, et al. Frequency distribution and risk factors of hepatitis B virus and hepatitis C virus infections among thalassemia patients: a regional study. Eur J Gastroenterol Hepatol. 2019;31(2):248–52.PubMedCrossRef
40.
de Melo Silva J, Pinheiro-Silva R, Dhyani A, Pontes GS. Cytomegalovirus and Epstein-Barr Infections: Prevalence and Impact on Patients with Hematological Diseases. Biomed Res Int. 2020;2020:1627824.PubMedPubMedCentralCrossRef
41.
Sornjai W, Khungwanmaythawee K, Svasti S, Fucharoen S, Wintachai P, Yoksan S, et al. Dengue virus infection of erythroid precursor cells is modulated by both thalassemia trait status and virus adaptation. Virology. 2014;471–473:61–71.PubMedCrossRef
42.
Krause MA, Diakite SA, Lopera-Mesa TM, Amaratunga C, Arie T, Traore K, et al. α-Thalassemia impairs the cytoadherence of Plasmodium falciparum-infected erythrocytes. PLoS ONE. 2012;7(5):e37214.PubMedPubMedCentralCrossRef
43.
Kumari N, Ammosova T, Diaz S, Lin X, Niu X, Ivanov A, et al. Increased iron export by ferroportin induces restriction of HIV-1 infection in sickle cell disease. Blood Adv. 2016;1(3):170–83.PubMedPubMedCentralCrossRef
44.
Nekhai S, Kumari N. HIV-1 infection in sickle cell disease and sickle cell trait: role of iron and innate response. Expert Rev Hematol. 2022;15(3):253–63.PubMedPubMedCentralCrossRef
45.
Ahamed SG, Ibrahim UA, Kagu MB. Synergistic protective effect of Sickle Cell Trait and Blood Group-O on the risk of endemic Burkitt’s Lymphoma. Gulf J Oncol. 2018;1(28):11–6.
46.
Archer NM, Petersen N, Clark MA, Buckee CO, Childs LM, Duraisingh MT. Resistance to Plasmodium falciparum in sickle cell trait erythrocytes is driven by oxygen-dependent growth inhibition. Proc Natl Acad Sci USA. 2018;115(28):7350–5.PubMedPubMedCentralCrossRef
47.
Nkhoma ET, Poole C, Vannappagari V, Hall SA, Beutler E. The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. Blood Cells Mol Dis. 2009;42(3):267–78.PubMedCrossRef
48.
Tong Y, Liu B, Zheng H, Bao A, Wu Z, Gu J, et al. A novel G6PD deleterious variant identified in three families with severe glucose-6-phosphate dehydrogenase deficiency. BMC Med Genet. 2020;21(1):150.PubMedPubMedCentralCrossRef
49.
Organization WH. WHO malaria policy advisory group (MPAG) meeting: meeting report, March 2022. 2022 924004843X.
50.
da Rocha J, Othman H, Tiemessen CT, Botha G, Ramsay M, Masimirembwa C et al. G6PD variant distribution in sub-Saharan Africa and potential risks of using chloroquine/hydroxychloroquine based treatments for COVID-19. medRxiv: the preprint server for health sciences. 2020.
51.
Clark TG, Fry AE, Auburn S, Campino S, Diakite M, Green A, et al. Allelic heterogeneity of G6PD deficiency in West Africa and severe malaria susceptibility. Eur J Hum genetics: EJHG. 2009;17(8):1080–5.PubMedCrossRef
52.
Li Q, Yang F, Liu R, Luo L, Yang Y, Zhang L, et al. Prevalence and molecular characterization of Glucose-6-Phosphate Dehydrogenase Deficiency at the China-Myanmar Border. PLoS ONE. 2015;10(7):e0134593.PubMedPubMedCentralCrossRef
53.
Laosombat V, Sattayasevana B, Chotsampancharoen T, Wongchanchailert M. Glucose-6-phosphate dehydrogenase variants associated with favism in thai children. Int J Hematol. 2006;83(2):139–43.PubMedCrossRef
54.
55.
Howes RE, Dewi M, Piel FB, Monteiro WM, Battle KE, Messina JP, et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J. 2013;12:418.PubMedPubMedCentralCrossRef
56.
Yi H, Li H, Liang L, Wu Y, Zhang L, Qiu W, et al. The glucose-6-phosphate dehydrogenase Mahidol variant protects against uncomplicated Plasmodium vivax infection and reduces disease severity in a Kachin population from northeast Myanmar. Infect Genet evolution: J Mol Epidemiol evolutionary Genet Infect Dis. 2019;75:103980.CrossRef
57.
Phompradit P, Kuesap J, Chaijaroenkul W, Rueangweerayut R, Hongkaew Y, Yamnuan R, et al. Prevalence and distribution of glucose-6-phosphate dehydrogenase (G6PD) variants in Thai and burmese populations in malaria endemic areas of Thailand. Malar J. 2011;10:368.PubMedPubMedCentralCrossRef
58.
May WL, Kyaw MP, Blacksell SD, Pukrittayakamee S, Chotivanich K, Hanboonkunupakarn B, et al. Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children. PLoS ONE. 2019;14(1):e0209204.PubMedPubMedCentralCrossRef
59.
Chao YC, Huang CS, Lee CN, Chang SY, King CC, Kao CL. Higher infection of dengue virus serotype 2 in human monocytes of patients with G6PD deficiency. PLoS ONE. 2008;3(2):e1557.PubMedPubMedCentralCrossRef
60.
Yang HC, Ma TH, Tjong WY, Stern A, Chiu DT. G6PD deficiency, redox homeostasis, and viral infections: implications for SARS-CoV-2 (COVID-19). Free Radic Res. 2021:1–11.
61.
Jamerson BD, Haryadi TH, Bohannon A. Glucose-6-Phosphate dehydrogenase Deficiency: an actionable risk factor for patients with COVID-19? Arch Med Res. 2020;51(7):743–4.PubMedPubMedCentralCrossRef
62.
Town M, Bautista JM, Mason PJ, Luzzatto L. Both mutations in G6PD A — are necessary to produce the G6PD deficient phenotype. Hum Mol Genet. 1992;1(3):171–4.PubMedCrossRef
63.
Shah SS, Macharia A, Makale J, Uyoga S, Kivinen K, Craik R, et al. Genetic determinants of glucose-6-phosphate dehydrogenase activity in Kenya. BMC Med Genet. 2014;15:93.PubMedPubMedCentralCrossRef
64.
Charoenkwan P, Tantiprabha W, Sirichotiyakul S, Phusua A, Sanguansermsri T. Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase deficiency in northern Thailand. Southeast Asian J Trop Med Public Health. 2014;45(1):187–93.PubMed
65.
Manjurano A, Sepulveda N, Nadjm B, Mtove G, Wangai H, Maxwell C, et al. African glucose-6-phosphate dehydrogenase alleles associated with protection from severe malaria in heterozygous females in Tanzania. PLoS Genet. 2015;11(2):e1004960.PubMedPubMedCentralCrossRef
66.
Aka P, Kawira E, Masalu N, Emmanuel B, Brubaker G, Magatti J, et al. Incidence and Trends in Burkitt Lymphoma in Northern Tanzania from 2000 to 2009. Pediatr Blood Cancer. 2012;59(7):1234–8.PubMedPubMedCentralCrossRef
67.
Legason ID, Pfeiffer RM, Udquim K-I, Bergen AW, Gouveia MH, Kirimunda S, et al. Evaluating the Causal Link between Malaria infection and endemic Burkitt Lymphoma in Northern Uganda: a mendelian randomization study. EBioMedicine. 2017;25:58–65.PubMedPubMedCentralCrossRef
68.
Daud II, Coleman CB, Smith NA, Ogolla S, Simbiri K, Bukusi EA, et al. Breast milk as a potential source of Epstein-Barr Virus Transmission among Infants living in a Malaria-Endemic Region of Kenya. J Infect Dis. 2015;212(11):1735–42.PubMedPubMedCentralCrossRef
69.
Yone CL, Kube D, Kremsner PG, Luty AJ. Persistent Epstein-Barr viral reactivation in young african children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 2006;100(7):669–76.PubMedCrossRef
70.
71.
Osier FH, Fegan G, Polley SD, Murungi L, Verra F, Tetteh KK, et al. Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infect Immun. 2008;76(5):2240–8.PubMedPubMedCentralCrossRef
72.
Taylor RR, Allen SJ, Greenwood BM, Riley EM. IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg. 1998;58(4):406–13.PubMedCrossRef
73.
Metzger WG, Okenu DM, Cavanagh DR, Robinson JV, Bojang KA, Weiss HA, et al. Serum IgG3 to the Plasmodium falciparum merozoite surface protein 2 is strongly associated with a reduced prospective risk of malaria. Parasite Immunol. 2003;25(6):307–12.PubMedCrossRef
74.
Niang M, Loucoubar C, Sow A, Diagne MM, Faye O, Faye O, et al. Genetic diversity of Plasmodium falciparum isolates from concurrent malaria and arbovirus co-infections in Kedougou, southeastern Senegal. Malar J. 2016;15:155.PubMedPubMedCentralCrossRef
75.
Murungi LM, Sondén K, Llewellyn D, Rono J, Guleid F, Williams AR, et al. Targets and Mechanisms Associated with Protection from severe Plasmodium falciparum malaria in kenyan children. Infect Immun. 2016;84(4):950–63.PubMedPubMedCentralCrossRef
76.
al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, Baisor M, et al. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New guinean children from malaria morbidity. Am J Trop Med Hyg. 1996;54(5):443–8.PubMedCrossRef
77.
Egan AF, Morris J, Barnish G, Allen S, Greenwood BM, Kaslow DC, et al. Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis. 1996;173(3):765–9.PubMedCrossRef
78.
Riley EM, Wagner GE, Ofori MF, Wheeler JG, Akanmori BD, Tetteh K, et al. Lack of association between maternal antibody and protection of african infants from malaria infection. Infect Immun. 2000;68(10):5856–63.PubMedPubMedCentralCrossRef
79.
Boyle MJ, Reiling L, Feng G, Langer C, Osier FH, Aspeling-Jones H, et al. Human antibodies fix complement to inhibit Plasmodium falciparum invasion of erythrocytes and are associated with protection against malaria. Immunity. 2015;42(3):580–90.PubMedPubMedCentralCrossRef
80.
Osier FH, Feng G, Boyle MJ, Langer C, Zhou J, Richards JS, et al. Opsonic phagocytosis of Plasmodium falciparum merozoites: mechanism in human immunity and a correlate of protection against malaria. BMC Med. 2014;12:108.PubMedPubMedCentralCrossRef
81.
Long HM, Taylor GS, Rickinson AB. Immune defence against EBV and EBV-associated disease. Curr Opin Immunol. 2011;23(2):258–64.PubMedCrossRef
Metadata
Title
Hemoglobinopathies, merozoite surface protein-2 gene polymorphisms, and acquisition of Epstein Barr virus among infants in Western Kenya
Authors
Perez K. Olewe
Shehu Shagari Awandu
Elly O. Munde
Samuel B. Anyona
Evans Raballah
Asito S. Amolo
Sidney Ogola
Erick Ndenga
Clinton O. Onyango
Rosemary Rochford
Douglas J. Perkins
Collins Ouma
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-11063-2

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue

Research

MicroRNA-5195-3p mediated malignant biological behaviour of insulin-resistant liver cancer cells via SOX9 and TPM4

Research

Clinicopathological features and prognosis of patients with HER2-low breast cancer

Research

Clinical retrospective analysis with a predictive model for diffused-tenosynovial giant cell tumors of the temporomandibular joint

Research

Shooting the messenger: a systematic review investigating extracellular vesicle isolation and characterisation methods and their influence on understanding extracellular vesicles-radiotherapy interactions in glioblastoma

Research

An analysis of clinical characteristics and prognosis of endometrioid ovarian cancer based on the SEER database and two centers in China

Research

Improved uptake and survival with systemic treatments for metastatic non-small cell lung cancer: younger versus older adults
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits